Drugs / VHB937
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07094516 | Aug 2025 → Sep 2028 expected | Alzheimer disease | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06643481 | Oct 2024 → Jun 2026 overdue | amyotrophic lateral sclerosis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VHB937 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07094516 ↗ |
| Route | Intravenous | “I.V. infusions” NCT06643481 ↗ |